Joshi, U. M., Zarka, J., Wang, H., Zang, Y., Rose, A., Kirkwood, J. M., Luke, J. J., Zarour, H. M., Davar, D., Najjar, Y. G. (2025). A phase 1/2 study of vusolimogene oderparepvec (RP1) in primary melanoma (mel) to reduce the risk of sentinel lymph node (SLN) metastasis.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps9607